Analysis of serum S100A12, soluble advanced glycation end products receptor, and gut microbiome in elderly patients with colorectal cancer

Table 1 Comparison of serum S100 calcium-binding protein A12 and soluble receptor for advanced glycation end products levels before chemotherapy in patients with colorectal cancer with different gut microbiota conditions

Group	S100A12 (μg/L)	sRAGE (ng/L)
Normal microbiota (n = 50)	265.37 ± 45.74	381.56 ± 36.78
Mild dysbiosis (n = 43)	302.53 ± 56.97b,1	441.38 ± 48.73b,1
Severe dysbiosis (n = 27)	340.26 ± 52.39a,b,1,2	525.64 ± 37.32a,b,1,2
F value	19.162	105.972
P value	< 0.001	< 0.001

^aP < 0.05.

^bP < 0.01.

¹P vs normal group.

²P vs mild dysbiosis group.

S100A12: S100 calcium-binding protein A12; sRAGE: Soluble receptor for advanced glycation end products.

Table 2 Correlation between serum S100 calcium-binding protein A12 and soluble receptor for advanced glycation end products levels and gut microbiota dysbiosis in patients with colorectal cancer

Indicator	S100A12		sRAGE
	r	P value	r	P value
Escherichia coli	0.551	< 0.001	0.627	< 0.001
Enterococcus faecalis	0.587	< 0.001	0.529	< 0.001
Bifidobacterium	-0.623	< 0.001	-0.584	< 0.001
Lactobacillus	-0.615	< 0.001	-0.606	< 0.001

S100A12: S100 calcium-binding protein A12; sRAGE: Soluble receptor for advanced glycation end products.

Table 3 Predictive diagnostic value of pre-chemotherapy serum S100 calcium-binding protein A12 and soluble receptor for advanced glycation end products levels for chemotherapy ineffectiveness in colorectal cancer

Indicator	Optimal cutoff value	AUC	95%CI	P value	Sensitivity (%)	Specificity (%)
S100A12	324.89 μg/L	0.802	0.713-0.864	< 0.05	79.04	82.03
sRAGE	435.76 ng/L	0.841	0.776-0.915	< 0.05	81.43	75.32
Combined	-	0.914	0.843-0.962	< 0.05	86.07	88.89

AUC: Area under the curve; CI: Confidence interval; S100A12: S100 calcium-binding protein A12; sRAGE: Soluble receptor for advanced glycation end products.